AxoGen, Inc.

AxoGenInc.com

It's time to rethink nerve repair! AxoGen (NASDAQ: AXGN) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. People suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. Damage may cause loss of function and feeling. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft for bridging nerve discontinuities, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the healing process.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

news image

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More

Industrial Impact

BIOCONSORTIA SHOWCASES BREAKTHROUGH MICROBIAL PRODUCTS AND PIPELINE OF INNOVATION

BioConsortia, Inc. | September 05, 2022

news image

BioConsortia’s innovative microbial products and technical capabilities were on full display August 30th at its Davis, CA headquarters in an investor-focused Technology Showcase event. BioConsortia demonstrated rapid advancements in microbial product and pipeline developments for reducing nitrogen fertilizers, controlling soil pests and plant diseases for larger and better-quality crop yields, as well as protecting crops post-harvest to avoid food waste, while minimizing environmental impa...

Read More

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

news image

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More

Diagnostics

OXFORD BIOTHERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH IMMUNOGEN TO DEVELOP NOVEL ANTIBODY-DRUG CONJUGATES

Oxford BioTherapeutics | June 14, 2022

news image

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen's linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discove...

Read More
news image

Cell and Gene Therapy

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More
news image

Industrial Impact

BIOCONSORTIA SHOWCASES BREAKTHROUGH MICROBIAL PRODUCTS AND PIPELINE OF INNOVATION

BioConsortia, Inc. | September 05, 2022

BioConsortia’s innovative microbial products and technical capabilities were on full display August 30th at its Davis, CA headquarters in an investor-focused Technology Showcase event. BioConsortia demonstrated rapid advancements in microbial product and pipeline developments for reducing nitrogen fertilizers, controlling soil pests and plant diseases for larger and better-quality crop yields, as well as protecting crops post-harvest to avoid food waste, while minimizing environmental impa...

Read More
news image

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More
news image

Diagnostics

OXFORD BIOTHERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH IMMUNOGEN TO DEVELOP NOVEL ANTIBODY-DRUG CONJUGATES

Oxford BioTherapeutics | June 14, 2022

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen's linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discove...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us